KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes.

Judith A H M Peeters, Jaap F Hamming, Paul H A Quax, Abbey Schepers

Ann Vasc Surg 130 282-289

PMID42119725
PMCID-
DOI10.1016/j.avsg.2026.04.044
发表日期2026-05-12
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: To evaluate the efficacy and safety of REX-001, an autologous bone marrow-derived mononuclear cell product, in patients with chronic limb-threatening ischemia (CLTI) who had no options for revascularization. METHODS: In this multicenter, double-blind, randomized, placebo-controlled phase III clinical trial, diabetic patients with CLTI (Rutherford category 5), no revascularization options, and no urgent need for amputation were enrolled. Bone marrow (250 mL) was processed to create REX-001, and a single intra-arterial injection was administered. Primary endpoints included change in Rutherford classification (to category 4 or lower) or complete ulcer healing within 12 months. Secondary endpoints included limb TcpO2, ulcer size, quality of life, ankle-brachial index, 6-min walking test, and amputation-free survival. RESULTS: The trial was stopped early after an interim analysis of 50% of the patients due to lack of efficacy. Thirty-two patients completed the study (21 REX-001, 11 placebo). Complete ulcer healing or improvement in Rutherford category occurred in 28.6% of REX-001-treated patients and 27.3% of placebo-treated patients. No treatment-related adverse events or safety concerns were identified. Data on secondary endpoints were not available. CONCLUSION: This prematurely ended study failed to confirm REX-001's efficacy for ulcer healing. Nevertheless, the study provides valuable insights into trial design, endpoint selection, and data stewardship, guiding future regenerative therapy research in this challenging patient population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。